The American Journal of Managed Care

Top 5 Most-Read AML Content of 2025

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
Fred Hutch

AML review: Diagnosis, treatment and what's new

New developments in the complex and rapidly changing world of acute myeloid leukemia (AML) promise to improve health outcomes for people with the disease. They include: Advances in diagnostics ...
Cure Today

Midostaurin Granted an FDA Priority Review for AML

Midostaurin was granted a priority review for a new drug application by the FDA to treat a subset of patients with acute myeloid leukemia. Midostaurin (PKC412) was granted a priority review to a new ...
Nasdaq

Astellas' XOSPATA® (gilteritinib) Meets Overall Survival Endpoint in COMMODORE Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

TOKYO, March 29, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that a Phase 3 confirmatory trial of XOSPATA® (gilteritinib ...